viewKazia Therapeutics Ltd

Kazia Therapeutics designated name for brain cancer drug by World Health Organisation

Selection of an INN is usually a necessary step before a new drug can be submitted for commercial registration.

Kazia Therapeutics Ltd - Kazia Therapeutics' new drug selected by World Health Organisation with paxalisib as INN
The commercial brand name for GDC-0084 has not yet been chosen and will be developed as the drug nears a commercial registration

Kazia Therapeutics Ltd’s (ASX:KZA) new investigational drug GDC-0084 has been selected by the World Health Organisation (WHO) with ‘paxalisib’ as the proposed international non-proprietary name (INN).

The company is developing GDC-0084 for the treatment of various forms of brain cancer and the selection of paxalisib as an INN represents an important regulatory milestone.

It provides a more identifiable name for clinicians and researchers to use in relation to the drug and follows standard naming conventions laid down by WHO.

The lead is glioblastoma, the most common and most aggressive form of primary brain cancer with four clinical studies currently underway and expected data due in the second half of 2019.

INN details

The name has been published by WHO in the 121st list of proposed international non-proprietary names on August 21.

The proposed name is subject to a four-month period before paxalisib can be confirmed as the INN.

Once the selection procedure is complete the name will be formalised by the end of 2019 and Kazia will begin including the name in documentation and communications relating to GDC-0084.


New drugs typically receive at least three names during their development with the first being a company code number used for internal administration purposes during the early stages of development.

The INN is chosen around the time of phase II clinical trials and is used to refer to any product that contains that active drug.

An example of an INN is paracetamol, which is used in the description of any product containing that drug as an active ingredient.

Quick facts: Kazia Therapeutics Ltd

Price: 0.52 AUD

Market: ASX
Market Cap: $37.53 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...



Kazia Therapeutics working on moving its flagship Paxalisib drug into...

  Kazia Therapeutics Ltd's (ASX:KZA) James Garner speaks to Proactive's Andrew Scott after releasing a poster presentation of interim data from the ongoing phase II study of Paxalisib in glioblastoma at the prestigious American Society of Clinical Oncology (ASCO) annual meeting. Analysis...

on 06/04/2020

2 min read